All adolescents articles
-
News
Valneva reports high sustained immune response in adolescents one year after Chikungunya Vaccine
Valneva SE, a specialty vaccine company, has reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination.
-
News
Mpox vaccine is safe and generates a robust antibody response in adolescents
A clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to a planned interim analysis of study data.